BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12223444)

  • 1. A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity.
    Qiu W; Campbell RL; Gangloff A; Dupuis P; Boivin RP; Tremblay MR; Poirier D; Lin SX
    FASEB J; 2002 Nov; 16(13):1829-31. PubMed ID: 12223444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
    Mazumdar M; Fournier D; Zhu DW; Cadot C; Poirier D; Lin SX
    Biochem J; 2009 Dec; 424(3):357-66. PubMed ID: 19929851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
    Fournier D; Poirier D; Mazumdar M; Lin SX
    Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
    Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estradiol-adenosine hybrid compounds designed to inhibit type 1 17beta-hydroxysteroid dehydrogenase.
    Poirier D; Boivin RP; Tremblay MR; Bérubé M; Qiu W; Lin SX
    J Med Chem; 2005 Dec; 48(26):8134-47. PubMed ID: 16366595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of fused 16β,17β-oxazinone-estradiol derivatives as a new family of non-estrogenic 17β-hydroxysteroid dehydrogenase type 1 inhibitors.
    Maltais R; Trottier A; Delhomme A; Barbeau X; Lagüe P; Poirier D
    Eur J Med Chem; 2015 Mar; 93():470-80. PubMed ID: 25728028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved synthesis of EM-1745, preparation of its C17-ketone analogue and comparison of their inhibitory potency on 17beta-hydroxysteroid dehydrogenase type 1.
    Bérubé M; Poirier D
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):832-43. PubMed ID: 19003559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and preliminary evaluation of a modified estradiol-core bearing a fused γ-lactone as non-estrogenic inhibitor of 17β-hydroxysteroid dehydrogenase type 1.
    Ouellet E; Ayan D; Poirier D
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5510-3. PubMed ID: 21782424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
    Karkola S; Alho-Richmond S; Wahala K
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of simplified hybrid inhibitors of type 1 17beta-hydroxysteroid dehydrogenase via cross-metathesis and sonogashira coupling Reactions.
    Bérubé M; Poirier D
    Org Lett; 2004 Sep; 6(18):3127-30. PubMed ID: 15330604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The derivation of a potential transition state for the reduction reaction catalysed by 17beta-hydroxysteroid dehydrogenase--an approximate representation of its active site for use in drug design and discovery.
    Owen CP; Ahmed S
    Biochem Biophys Res Commun; 2004 May; 318(1):131-4. PubMed ID: 15110763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping of steroids binding to 17 beta-hydroxysteroid dehydrogenase type 1 using Monte Carlo energy minimization reveals alternative binding modes.
    Blanchet J; Lin SX; Zhorov BS
    Biochemistry; 2005 May; 44(19):7218-27. PubMed ID: 15882060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
    Aka JA; Mazumdar M; Lin SX
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):183-90. PubMed ID: 19038308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis of the multispecificity demonstrated by 17beta-hydroxysteroid dehydrogenase types 1 and 5.
    Lin SX; Shi R; Qiu W; Azzi A; Zhu DW; Dabbagh HA; Zhou M
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):38-46. PubMed ID: 16480815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation.
    Tremblay MR; Poirier D
    J Steroid Biochem Mol Biol; 1998 Aug; 66(4):179-91. PubMed ID: 9744515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Brozic P; Lanisnik Risner T; Gobec S
    Curr Med Chem; 2008; 15(2):137-50. PubMed ID: 18220769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
    Laplante Y; Cadot C; Fournier MA; Poirier D
    Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Allan GM; Lawrence HR; Cornet J; Bubert C; Fischer DS; Vicker N; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
    J Med Chem; 2006 Feb; 49(4):1325-45. PubMed ID: 16480268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Fischer DS; Allan GM; Bubert C; Vicker N; Smith A; Tutill HJ; Purohit A; Wood L; Packham G; Mahon MF; Reed MJ; Potter BV
    J Med Chem; 2005 Sep; 48(18):5749-70. PubMed ID: 16134943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.